BACKGROUND AND AIMS: Mycobacterium leprae is an obligate intracellular pathogen. Ligand-binding is an important factor in the success of chemoprevention and chemotherapy. A new drug that can inhibit M. leprae binding to and activation of, ErbB2 and Erk1/2 in primary Schwann cells is the new therapeutic option. However, the ligand-binding pattern of ErbB2 has never been clarified.
METHODS: In this work, the author performed a ligand-binding prediction for ErbB2 using a new bioinformatics tool.
RESULTS: According to this study, nine strong possible ligands can be identified.
CONCLUSION: These sites can be useful for further drug-development studies.
BT - Indian journal of dermatology, venereology and leprology C1 - http://www.ncbi.nlm.nih.gov/pubmed/18187820?dopt=Abstract DA - 2008 Jan-Feb IS - 1 J2 - Indian J Dermatol Venereol Leprol LA - eng N2 -BACKGROUND AND AIMS: Mycobacterium leprae is an obligate intracellular pathogen. Ligand-binding is an important factor in the success of chemoprevention and chemotherapy. A new drug that can inhibit M. leprae binding to and activation of, ErbB2 and Erk1/2 in primary Schwann cells is the new therapeutic option. However, the ligand-binding pattern of ErbB2 has never been clarified.
METHODS: In this work, the author performed a ligand-binding prediction for ErbB2 using a new bioinformatics tool.
RESULTS: According to this study, nine strong possible ligands can be identified.
CONCLUSION: These sites can be useful for further drug-development studies.
PY - 2008 SP - 32 EP - 4 T2 - Indian journal of dermatology, venereology and leprology TI - Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy. UR - http://www.ijdvl.com/text.asp?2008/74/1/32/38404 VL - 74 SN - 0973-3922 ER -